Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Human Genetics, |
RCV000659550 | SCV000781381 | pathogenic | Marfan syndrome | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000696440 | SCV000825002 | pathogenic | Marfan syndrome; Thoracic aortic aneurysm and aortic dissection | 2018-05-10 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 41 of the FBN1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individuals affected with Marfan syndrome (PMID: 19159394, Invitae). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in FBN1 are known to be pathogenic (PMID: 17657824, 19293843). For these reasons, this variant has been classified as Pathogenic. |
Center for Medical Genetics Ghent, |
RCV000659550 | SCV000787109 | likely pathogenic | Marfan syndrome | 2017-11-07 | no assertion criteria provided | clinical testing |